You signed in with another tab or window. Reload to refresh your session.You signed out in another tab or window. Reload to refresh your session.You switched accounts on another tab or window. Reload to refresh your session.Dismiss alert
Cost-effectiveness microsimulation model for IXA-001 (aldosterone synthase inhibitor) vs Spironolactone in resistant hypertension. Features dual-branch phenotyping, PA risk modifiers, AF tracking, and interactive Streamlit dashboard.
Budget impact model for IXA-001 in resistant hypertension. Features population funnel analysis, uptake scenarios, secondary HTN etiology stratification, and interactive Streamlit dashboard with Excel exports.